TerminatedNot Applicable

RESIST-2: 2nd-line ART for HIV-2 Infection

Stopped: COVID-19 and Funding

Senegal152 participantsStarted 2018-07-04

Plain-language summary

Prospective, longitudinal, open label, HIV-2 viral load and antiretroviral resistance informed 2nd-line ARV implementation study.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. HIV-2 infection: confirmed by Determine (Alere, Inc.) \& Immunocomb II (Alere, Inc.) or equivalent
✓. Failing 1st line antiretroviral therapy (e.g. AZT/3TC or TDF/XTC + LPV/r; previous 3 NRTI or 2 NRTI regimens; previous Indinavir (IDV) use, current or previous Atazanavir (ATV) use; previous NNRTI use)
✓. For females of reproductive potential: negative serum or urine pregnancy test
✓. Men and women age \>/=18 years
✓. Ability and willingness of subject to provide informed consent

Death

Timeframe: up to 3 years

Loss to follow up

Timeframe: 1 year

Virologic Failure on 2nd line ART

Timeframe: up to 3 years

HIV-2 ARV resistance on 2nd line ART

Timeframe: up to 3 years

NCT IDNCT03394196

SponsorUniversity of Washington

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-05-31